Lexicon Pharmaceuticals Q4 2025 Preview: Inpefa Growth in Focus
Lexicon Pharmaceuticals is set to report its Q4 2025 results, with investors focused on the commercial trajectory of its heart failure drug, Inpefa. The briefing examines the company's path to profitability and the regulatory landscape for its pipeline candidates.